Dr. Drezner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
26901 76th Ave
New Hyde Park, NY 11040Phone+1 718-470-3000Fax+1 202-476-5988
Education & Training
- Children's National Hospital/George Washington UniversityFellowship, Pediatric Hematology/Oncology, 2012 - 2015
- Zucker School of Medicine at Hofstra/Northwell at Cohen Children's Medical CenterResidency, Pediatrics, 2008 - 2012
- St. George's University School of MedicineClass of 2008
Certifications & Licensure
- DC State Medical License 2012 - 2026
- NY State Medical License 2011 - 2013
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.Sonia Singh, Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie L Aungst
Clinical Cancer Research. 2025-01-14 - US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.Elizabeth S Duke, Diana Bradford, Arup K Sinha, Pallavi S Mishra-Kalyani, Catherine C Lerro
Journal of Clinical Oncology. 2024-09-01 - FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller
Clinical Cancer Research. 2024-08-15
Press Mentions
- FDA Panel Endorses DFMO for Kids' High-Risk Neuroblastoma in RemissionOctober 6th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: